BPC-157 Pharmacokinetics
BPC-157 half-life, absorption, routes of administration, and clearance.
The Pharmacokinetic Precision Gap
Researchers often cite estimated metabolic rates for BPC-157, but precise preclinical data provides a more nuanced understanding of its therapeutic behavior. Understanding the interplay between its rapid clearance and its prolonged biological effect is essential for interpreting its unique research applications.
Systemic Half-Life: The 15.2-Minute Reality
Formal pharmacokinetic studies have established that BPC-157 is cleared from systemic circulation with remarkable speed. • Mean Elimination Half-Life (t½): In rats, the average elimination half-life after a single intravenous (IV) administration is 15.2 minutes. • Prototype Clearance: The prototype drug typically becomes undetectable in plasma within 4 hours post-administration. • Metabolic Fate: BPC-157 is primarily metabolized in the liver, where it is broken down into smaller peptide fragments and individual amino acids that enter normal metabolic pathways.
Physicochemical and PK profile
- Molecular Formula
- C62H98N16O22
- Molecular Weight
- 1419.53 g/mol
- CAS Number
- 137525-51-0
- Half-Life
- Under 30 minutes in animal PK; cleared from plasma within ~4 hours
- Sequence
- Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val
- Solubility
- Water soluble; bacteriostatic water recommended
- Storage
- Store lyophilized powder at -20°C. Reconstituted solution stable at 4°C for limited time.
References
- Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract
- Brain-gut axis and pentadecapeptide BPC 157
- Vasireddi N, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS Journal. 2025.
- Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain.
- Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing
- Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study.
- Chang CH, et al. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. 2014.
- Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study.
- Protective effects of pentadecapeptide BPC 157 on gastric ulcer in rats
- ClinicalTrials.gov. PCO-02 - Safety and Pharmacokinetics Trial.
- Pentadecapeptide BPC 157 shortens duration of tetracaine- and oxybuprocaine-induced corneal anesthesia in rats.
- The pharmacological properties of the novel peptide BPC 157 (PL-10)
- Bypassing major venous occlusion and duodenal lesions in rats, and therapy with the stable gastric pentadecapeptide BPC 157, L-NAME and L-arginine.